New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
09:17 EDTDOW, TLM, WHR, BRCM, BIIB, KING, REPYY, ISRG, PBYI, PEP, MCD, JNPR, ALTR, BA, GSK, XLNXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Intuitive Surgical (ISRG), up 12.8%... Biogen (BIIB), up 8%... Broadcom (BRCM), up 3.6%... PepsiCo (PEP), up 1.8%... Dow Chemical (DOW), up 1.5%. ALSO HIGHER: Puma Biotechnology (PBYI), up 275% after reporting positive top line results from Phase III PB272 trial, price target on stock raised to $325 from $125 at UBS, Citigroup says company a likely acquisition target after data... Talisman Energy (TLM), up 9.6% after Bloomberg reports Repsol (REPYY) may be looking to acquire. DOWN AFTER EARNINGS: Whirlpool (WHR), down 4.4%... Juniper Networks (JNPR), down 7.9%... GlaxoSmithKline (GSK), down 5.8%... Boeing (BA), down 0.8%. ALSO LOWER: Xilinx (XLNX), down 14.2% after results, downgrades at William Blair, BofA/Merrill and BMO Capital. Shares of peer Altera (ALTR) are also down 4.6%... King Digital (KING), down 2.7% after downgraded at BofA/Merrill... McDonald's (MCD), down 0.9% following downgrades at multiple firms after its earnings report yesterday.
News For PBYI;BA;MCD;XLNX;ALTR;PEP;GSK;JNPR;WHR;ISRG;BIIB;TLM;REPYY;BRCM;DOW;KING From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
May 13, 2015
11:15 EDTBASouthwest sees FY15 CapEx approximately $1.8B
Subscribe for More Information
09:56 EDTBRCMEquity options with increasing volume
Subscribe for More Information
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
06:11 EDTBABoeing ends work on only small satellite program, WSJ reports
Boeing is no longer working on a program for HySpecIQ, a private equity-backed startup, which had ordered two Boeing 502 Phoenix satellites that were expected to be launched in 2018, The Wall Street Journal reports. Boeing has ended work on the imaging spacecraft, its only small satellite order, due to the downturn in the natural resources market, the publication adds.
05:58 EDTALTRStocks with implied volatility above IV index mean; ALTR CSCO
Stocks with implied volatility above IV index mean; Altera (ALTR) 81, Cisco (CSCO) 27 according to iVolatility.
May 12, 2015
10:58 EDTBABoeing backs FY15 core EPS $8.20-$8.40, consensus $8.55
Subscribe for More Information
10:52 EDTBABoeing reports backlog of $440B in commercial airplanes
Subscribe for More Information
10:49 EDTBABoeing backs FY15 revenue $94.5B-$96.5B, consensus $94.56B
Subscribe for More Information
10:37 EDTALTRAltera calls active on renewed takeover speculation
Subscribe for More Information
10:26 EDTALTRRumor: Altera moves up on renewed takeover chatter
Subscribe for More Information
10:20 EDTBABoeing says demand for new airplanes remain high
CEO Jim McNerney comments that airlines remain increasingly profitable, allowing for more resources for new technology. He adds that the fundamentals that bear on market demand are there. Expects cash flow to continue to increase in 2016 and beyond on higher production rates and overall ongoing productivity gains across the company. See potential for higher margin in the long-term. Comments taken from May Investor Conference.
10:01 EDTISRGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTJNPROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:27 EDTPEP, BAU.S. Chamber of Commerce to hold a summit
Subscribe for More Information
07:24 EDTJNPRJuniper upgraded to Buy on new product cycles at BofA/Merrill
As previously reported, BofA/Merrill upgraded Juniper to Buy from Neutral. The firm expects Juniper's new products and sequential growth in North American carrier spending to drive growth in core business lines. BofA/Merrill said Juniper's new products address recent weaknesses in security, switching, and routing and expects growth and operating margins to begin to stabilize. Price target raised to $34 from $27.
06:19 EDTJNPRJuniper upgraded to Buy from Neutral at BofA/Merrill
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
06:00 EDTALTRStocks with implied volatility above IV index mean; ALTR CSCO
Subscribe for More Information
05:34 EDTISRGIntuitive Surgical initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use